Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of GSK Biologicals' (Pre-) Pandemic Influenza Candidate Vaccine

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Japanese male and female adults 20 to 64 years of age at time of the first vaccination, inclusive.~* Good general health as assessed by medical history and physical examination.~* Access to a consistent means of telephone contact, which may be either in the home or at the workplace, land line or mobile, but NOT a pay phone or other multiple-user device.~* Written informed consent obtained from the subject.~* Comprehension of the study requirements, expressed availability for the required study period, and ability to attend scheduled visits.~* Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study.~Exclusion Criteria:~* Presence of significant acute or chronic, uncontrolled medical or psychiatric illness.~* Presence or evidence of substance abuse or of neurological or psychiatric diagnoses which, although stable, are deemed by the investigator to render the potential subject unable/unlikely to provide accurate safety reports.~* Diagnosed with cancer, or treatment for cancer within 3 years.~* Presence of an axillary temperature \>= 37.5 °C, or acute symptoms greater than mild severity on the scheduled date of first vaccination.~* Any confirmed or suspected immunosuppressive or immunodeficient condition including history of human immunodeficiency virus (HIV) infection.~* Receipt of systemic glucocorticoids within 1 month of study enrolment, or any other cytotoxic or immunosuppressive drug within 6 months of study enrolment.~* Any significant disorder of coagulation or treatment with Coumadin derivatives or heparin.~* Administration of any registered vaccine within 30 days before study enrolment or planned administration within the first vaccination up to blood sampling at Day 42 and within 30 days prior to blood sampling at Day 182.~* Use of any investigational or non-registered product within 30 days prior to study enrolment or planned use during the study period.~* History of previous H5N1 vaccination, or history of H5N1 influenza infection.~* Receipt of any immunoglobulins and/or any blood products within 6 months of study enrolment or planned administration of any of these products during the study period.~* Any known or suspected allergy to any constituent of influenza vaccines or component used in the manufacturing process of the study vaccine, a history of anaphylactic-type reaction to consumption of eggs; or a history of severe adverse reaction to a previous influenza vaccine.~* Known pregnancy or a positive urine beta-human chorionic gonadotropin test result prior to the time of first vaccination.~* Lactating or nursing.~* Women of child-bearing potential who lack a history of reliable contraceptive practices. The provision of this history does NOT replace the requirement to perform, and obtain negative results in pregnancy urine tests prior to treatments; all women will have urine pregnancy tests regardless of their status.~* Known receipt of analgesic or antipyretic medication on the day of treatment (Day 0).

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- Influenza A (H5N1) 20-40 Years Group (Type: EXPERIMENTAL): Subjects aged between 20 and 40 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm.
- Influenza A (H5N1) 41-64 Years Group (Type: EXPERIMENTAL): Subjects aged between 41 and 64 years inclusive received 2 doses of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted at Days 0 and 21 administered intramuscularly in the deltoid region of the non-dominant arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).